Drugs / ONCR-177
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04348916 | May 2020 → May 2023 | colorectal carcinoma, head and neck squamous cell carcinoma, melanoma, skin cancer +1 | Oncorus, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ONCR-177 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04348916 ↗ |
| Action | Inhibit | “ONCR-177 is armed with five transgenes for IL12, FLT3LG (extracellular domain), CCL4, and antagonists to immune checkpoints PD-1 and CTLA-4.” PMID 33355229 ↗ Dec 2020 |
| Route | Other | “Intratumorally administered oncolytic immunotherapy comprised of a genetically engineered HSV-1” NCT04348916 ↗ |